No Data
No Data
Beijing Bohui Innovation Biotechnology Group (300318.SZ): Currently, the company has only obtained EU CE certification for its smallpox-related test kit, and the product has not yet been launched for sale.
On August 16, Gelonhui reported that Beijing Bohui Innovation Biotechnology Group (stock code: 300318.SZ) stated on the investor interaction platform that the company has currently only obtained the EU CE certification for its smallpox-related diagnostic kits, and the products are not yet on the market for sale.
Beijing Bohui Innovation Biotechnology Group (300318.SZ) has three products related to virus testing for influenza.
Beijing Bohui Innovation Biotechnology Group (300318.SZ) stated on the investor platform that there are three products related to virus testing: 1. Influenza A virus, influenza B virus, respiratory adenovirus, respiratory syncytial virus antigen combination test kit (immunofluorescence method), which is currently registered for listing. 2. Respiratory pathogen six-fold nucleic acid detection test kit (PCR-fluorescence probe method), which is currently in the stage of review and supplementary data. 3. Respiratory pathogen multiple nucleic acid detection test kit (biochip method), which has been listed for scientific research and can be used in the field of disease control centers and other areas.
Beijing Bohui Innovation Biotechnology Group (stock code: 300318.SZ) announced that its subsidiary plasma station has obtained a license for single-collection plasma.
Beijing Bohui Innovation Biotechnology Group (300318.SZ) announced on August 13th that its subsidiary, Bohui Biopharmaceuticals (Hebei) Co., Ltd.'s subordinate Yiliang Bohui Single Plasma Collection Co., Ltd. (hereinafter referred to as "Yiliang Plasma Station") and Yongshan Bohui Single Plasma Collection Co., Ltd. (hereinafter referred to as "Yongshan Plasma Station") have obtained the Single Plasma Collection License issued by the Health and Health Committee of Yunnan Province. Yiliang Plasma Station and Yongshan Plasma Station have been approved and registered and are allowed to practice.
Beijing Bohui Innovation Biotechnology Group (300318.SZ): The supplementary registration application for the Langfang Bohui Groundhog Kidney Rabies Vaccine has entered the data supplement stage.
Beijing Bohui Innovation Biotechnology Group (300318.SZ) stated on the investor interactive platform on July 30 that currently, the supplementary application for registration of the groundhog kidney rabies vaccine drug at Langfang Bohui has entered the stage of supplementary data preparation, and Langfang Bohui is fully preparing the data according to the requirements of the drug review center. After the supplementary application is officially approved in the future, production will resume, and it is expected to make a positive contribution to the company's operation performance. Please continue to pay attention to the company's regular reports for relevant financial data.
Beijing Bohui Innovation Biotechnology Group (300318.SZ): Currently, the company operates 16 pulp stations.
On July 15th, 2024, Beijing Bohui Innovation Biotechnology Group (300318.SZ) accepted a specific object investigation regarding the "planning of the company's pulp station quantity and collection volume". The company replied that it currently operates 16 pulp stations, with Hebei Bohui holding 9 of them, including 3 in Yunnan and 6 in Hebei. Guangdong Weilun holds 7 pulp stations, all of which are located in Guangdong. There are also 7 pulp stations in the stage of waiting for practice licenses or acceptance, with Hebei Bohui holding 5 of them, all of which are located in Yunnan. Three of them have completed the acceptance process and are waiting for practice licenses, and 2 have been completed. Guangdong Weilun holds 2 pulp stations, both of which are located in the interior.
Beijing Bohui Innovation Biotechnology Group (300318.SZ): The production registration application for human coagulation factor VIII is being prepared.
On June 25th, Gelunhui reported that Beijing Bohui Innovation Biotechnology Group (300318.SZ) accepted a specific object's investigation regarding the research and development progress of new products of Hebei Bohui and Guangdong Weilun (recumbent, 8 indicators, chromatographic propofol, etc.). The company replied that human fibronectin is conducting stability research and preclinical research. Human coagulation factor VIII is preparing for production and registration declaration work. The new process of Propofol is undergoing scale-up experimental research.
No Data